Bendamustine - Eagle Pharmaceuticals

Drug Profile

Bendamustine - Eagle Pharmaceuticals

Alternative Names: Bendamustine 500mL; Bendamustine 50mL; Bendamustine II; Bendamustine rapid infusion; Bendamustine RTD; Bendamustine shorter-infusion; Bendeka; EP-3101; EP-3102; RTD bendamustine

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Eagle Pharmaceuticals
  • Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
  • Mechanism of Action Antimetabolites; Apoptosis stimulants; DNA cross linking agents; DNA synthesis inhibitors; Mitosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Phase I Solid tumours

Most Recent Events

  • 21 Mar 2017 Eagle Pharmaceuticals has patent protection for bendamustine in USA
  • 01 Mar 2017 The Centers for Medicare & Medicaid Services established a unique J-Code (J9034) for bendamustine injection effective January 1, 2017
  • 22 Feb 2017 Eagle Pharmaceuticals has patent protection for bendamustine in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top